目的 探討艾愈膠囊聯(lián)合CAF化療方案治療乳腺癌患者的臨床療效。方法 選取2013-2015年宜昌市第二人民醫(yī)院收治的女性乳腺癌患者89例，隨機分為對照組（44例）和治療組（45例）。對照組靜脈推注注射用鹽酸多柔比星60 mg/m²，注射用環(huán)磷酰胺600 mg/m²，靜脈滴注氟脲嘧啶注射液500 mg/m²，第1、8天各1次，21 d為1個療程。治療組在對照組的基礎上口服艾愈膠囊，3粒/次，3次/d，21 d為1個療程。兩組均連續(xù)治療2個療程。觀察兩組的臨床療效，同時比較兩組治療前后血清血管內(nèi)皮生長因子（VEGF）、CA125、CA153和癌胚抗原（CEA）水平及不良反應情況。結果 治療后，對照組總有效率和穩(wěn)定率分別為34.09%和56.82%，分別低于治療組的57.78%和77.78%，兩組比較差異有統(tǒng)計學意義（P<0.05）。治療后，兩組血清VEGF、CA125、CA153和CEA水平均有一定程度降低，與治療前相比差異有統(tǒng)計學意義（P<0.05）。且治療組上述指標水平顯著低于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療期間，對照組患者白細胞和血紅蛋白減少發(fā)生率高于治療組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。結論 艾愈膠囊聯(lián)合CAF化療方案可以更好控制乳腺癌患者的VEGF以及相關腫瘤標志物水平，取得更好治療效果，具有一定的臨床推廣應用價值。

Objective To observe the clinical effect of Aiyu Capsules combined with CAF chemotherapy in treatment of breast cancer. Methods Female patients (89 cases) with breast cancer in the Second People's Hospital of Yichang from 2013 to 2015 were randomly divided into control (44 cases) and treatment (45 cases) groups. The patients in the control group were iv administered with Doxorubicin Hydrochloride for injection 60 mg/m² and Cyclophosphamide for injection 600 mg/m², and were iv administered with Fluorouracil Injection 500 mg/m², each time at the first and eighth day, 21 d for a course of treatment. in the treatment group were po administered with Aiyu Capsules on the basis of the control group, 3 grains/time, three times daily, 14 d for a course of treatment. The patients in two groups were treated for two courses of treatment. After treatment, the efficacy was observed, and the levels of VEGF, CA125, CA153, and CEA, and adverse reactions in two groups were compared. Results After treatment, the total efficacies and stable rate in the control group were 34.09% and 56.82%, respectively, and which were significantly lower than those (57.78% and 77.78%) in the treatment group, and there were differences between two groups (P<0.05). After treatment, the levels of VEGF, CA125, CA153, and CEA in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And these observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). During the treatment, white blood cell and hemoglobin decrease rate in the control group were significantly higher than those in the treatment group, and there were differences between two groups (P<0.05). Conclusion Aiyu Capsules combined with CAF chemotherapy can control VEGF and the related tumor markers of patients with breast cancer, achieve a better therapeutic effect, and which has a certain clinical application value.